Navarixin in Moderate to Severe COPD

• Navarixin 3 mg

  Navarixin 3 mg QD

• Navarixin 10 mg

  Navarixin 10 mg QD

• Navarixin 30 mg

  Navarixin 30 mg QD

• Placebo

  Placebo to match navarixin

Primary

• Number of Participants Who Experience at Least One Adverse Event (AE)12 weeks

• Number of Participants Who Discontinue Study Drug Due to an AE12 weeks

• Change From Baseline in Absolute Peripheral Blood Neutrophil (PBN) Count12 weeks

• Change From Baseline in Pre-bronchodilator Forced Expiratory Volume in 1 Second (FEV1)12 weeks

• Change From Baseline in Daily Morning/Nighttime Sputum Production, Cough, and Dyspnea (SCDS) Score12 weeks

Secondary

• Change From Baseline in Percent PBN Count12 weeks

• Change From Baseline in Sputum Absolute Neutrophil Count (Induced Sputum)12 weeks

• Change From Baseline in Post-Bronchodilator FEV112 weeks

• Change From Baseline in Forced Expiratory Flow During Middle Half of Forced Vital Capacity (FVC) (FEF25%-75%)12 weeks

• Change From Baseline in FVC12 weeks

• Change From Baseline in Functional Residual Capacity (FRC)12 weeks

• Number of Participants Who Experience a COPD Exacerbation12 weeks

• Change From Baseline in Peak Expiratory Flow (PEF)12 weeks